NASDAQ$NBIX

Neurocrine Biosciences Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Neurocrine Biosciences reported Q1 2025, revenue of $572.6M, net income of $89M, diluted EPS of $0.08.

For Q1 2025, Neurocrine Biosciences reported revenue of $572.6M, net income of $89M, diluted EPS was $0.08. The filing highlights segment performance, liquidity, and management commentary on the period.

  • Revenue $572.6M.
  • Net income $89M.
  • Diluted EPS $0.08.

Headline financials

Total Revenue

$573M

Previous: $515M+11.1%
EPS (adj)

$0.08

Previous: $0.42-81.0%
GAAP R&D Expense

$263M

Previous: $159M+65.1%
GAAP SG&A Expense

$277M

Previous: $243M+13.7%
Capital Expenditures

-$10.7M

Previous: -$11.2M+4.5%
Net Income

$7.9M

Previous: $43.4M-81.8%
Operating Income

$23.6M

Previous: $99.3M-76.2%

Revenue & EPS history

Neurocrine Biosciences · Revenue · Quarterly

$573M

Q1 2025+11.1%vs Q1 2024
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Neurocrine Biosciences · $486M total across 1 segment · Q3 2023

  • INGREZZA Net Product Sales
    $486M+29.3%

Forward guidance

Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.

Tailwinds

  • Headline results and segment trends anchor the quarter.
  • Liquidity and balance-sheet capacity support operations.
  • Strategic initiatives outlined in MD&A.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items affect year-over-year comparability.
  • Execution risk on growth or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-0.3%

Avg return

Earnings day

+1.1%

Avg return

5 days after

+1.6%

Avg return

30 days after

45%

29 / 65 earnings

Positive

+17.2%

Q3 2017

Best reaction

-18.5%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%+11.5%+21.3%
Q4 2025-10.4%-7.0%-5.6%
Q3 2025-6.3%-3.7%+3.2%
Q1 2025+8.3%+5.4%+13.5%
Q4 2024-18.5%-22.1%-24.9%
Q3 2024+3.5%+3.7%+9.1%
Q2 2024+8.2%+2.9%-10.2%
Q1 2024+1.7%+3.0%-1.5%
Q4 2023-6.0%-8.8%-2.6%
Q3 2023+4.1%+5.0%+8.8%
Q2 2023+2.2%-0.3%+6.9%
Q1 2023-7.4%-5.4%-10.8%
Q4 2022-5.6%-6.2%-11.1%
Q3 2022+6.0%+5.8%+9.7%
Q2 2022+10.6%+14.5%+9.5%
Q1 2022-3.9%-14.6%+7.7%
Q4 2021+8.7%+7.9%+12.2%
Q3 2021-9.3%-11.6%-23.4%
Q2 2021-2.8%-6.6%+0.4%
Q1 2021-2.3%-0.3%+3.2%
Q4 2020+3.1%+2.6%-17.3%
Q3 2020-9.1%-4.5%-4.5%
Q2 2020-0.2%-4.4%-3.7%
Q1 2020+7.0%+11.6%+13.8%
Q4 2019+2.0%+3.5%-5.4%
Q3 2019-1.2%+6.9%+14.4%
Q2 2019+9.7%+7.5%+11.3%
Q1 2019-6.7%+2.0%+1.4%
Q4 2018-4.6%-4.6%-12.9%
Q3 2018-8.0%-9.0%-25.5%
Q2 2018+14.7%+17.2%+23.3%
Q1 2018+3.3%+1.5%+17.1%
Q4 2017+3.9%+3.7%+11.6%
Q3 2017+17.2%+20.0%+18.5%
Q2 2017+10.2%+10.5%+17.4%
Q1 2017+3.4%+3.8%-15.3%
Q4 2016+0.7%+4.5%+7.2%
Q3 2016-10.0%-1.1%-3.1%
Q2 2016-0.7%-3.6%-2.0%
Q1 2016-0.1%
Q4 2015+6.9%
Q3 2015-4.5%
Q2 2015-3.7%
Q1 2015-4.4%
Q4 2014+5.7%
Q3 2014-4.9%
Q2 2014-2.3%
Q1 2014-3.5%
Q4 2013+1.3%
Q3 2013-6.3%
Q2 2013+0.5%
Q1 2013+2.3%
Q4 2012+6.5%
Q3 2012-1.7%
Q2 2012-9.6%
Q1 2011-3.2%
Q1 2012-3.2%
Q4 2011-8.0%
Q4 2009-8.0%
Q3 2010+13.7%
Q3 2011+13.7%
Q4 2010-6.5%
Q2 2010-6.5%
Q2 2011-6.5%
Q1 2010-1.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro